Please be advised that ordering of this test is restricted to locations participating in the Blood-Based Biomarker Sponsored Testing Program. If you are an ICL client looking to order pTau217 testing, please visit our test catalogue for more details.
Test Overview
Result Included
Phosphorylated Tau 217 (pTau217)
Specimen
Containers
Collection Containers
Lavender top (K2-EDTA)
Volume
Sample Volume
2.0 mL
Minimum Volume
0.5 mL
Collection & Handling
Collection Instructions
Separate within 4 hours. Store and send frozen.
Stability
Ambient |
Refrigerated |
Frozen |
|---|---|---|
3days |
7 days |
28 days |
Rejection Criteria
Criteria |
Specification |
|---|---|
Hemolysis |
Gross |
Performance & Interpretation
Turnaround Time
18 days
Result
Name |
Units |
Reference Range |
Conversion |
|---|---|---|---|
Phosphorylated Tau 217 (pTau217)
|
ng/L |
Negative: ≤0.13 |
|
|
Comment A negative result indicates a low likelihood that a patient’s cognitive impairment is due to Alzheimer’s disease (AD). A test result between 0.14 ng/L and 0.37 ng/L is considered intermediate. An intermediate result does not establish a diagnosis of AD or other cognitive disorder and has increased uncertainty in regard to amyloid PET positivity. A test result > 0.37 ng/L is positive and is consistent with a positive amylold PET scan and amyloid pathology of Alzheimer’s type. High pTau217 plasma levels alone do not establish a diagnosis of AD. Results should be interpreted in the context of other clinical signs and symptoms of AD. |
|||
Referral Location
Canada